

# Athanasios G Tzioufas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11876064/publications.pdf>

Version: 2024-02-01

202  
papers

9,592  
citations

28274

55  
h-index

42399

92  
g-index

206  
all docs

206  
docs citations

206  
times ranked

10159  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neutrophil extracellular traps in giant cell arteritis biopsies: presentation, localization and co-expression with inflammatory cytokines. <i>Rheumatology</i> , 2022, 61, 1639-1644.	1.9	17
2	Addressing the clinical unmet needs in primary Sjögren's Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 471-484.	4.1	7
3	Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis. <i>European Respiratory Journal</i> , 2022, 60, 2102951.	6.7	56
4	Clinical picture, outcome and predictive factors of lymphoma in primary Sjögren's syndrome: results from a harmonized dataset (1981-2021). <i>Rheumatology</i> , 2022, 61, 3576-3585.	1.9	19
5	Kinetics of Mononuclear Cell Subpopulations in the Peripheral Blood of Patients with Giant Cell Arteritis During the Acute Phase of the Disease: The Role of Steroids. <i>Mediterranean Journal of Rheumatology</i> , 2022, 33, 102.	0.8	0
6	Hashimoto Thyroiditis, Anti-Parietal Cell Antibodies: Associations With Autoimmune Diseases and Malignancies. <i>Frontiers in Endocrinology</i> , 2022, 13, 860880.	3.5	5
7	A past medical history of autoimmune disease predicts a future with fewer relapses in patients with ANCA-associated vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 741-750.	0.8	0
8	Late and booster anti-SARS-CoV-2 humoral responses in nonresponder vaccinated patients with rheumatic diseases receiving mycophenolate or rituximab: comment on the article by XXX et al. <i>ACR Open Rheumatology</i> , 2022, 4, 645-646.	2.1	1
9	COVID-19: Clinical features and outcomes in unvaccinated 2-dose and 3-dose vaccinated against SARS-CoV-2 patients with systemic autoimmune and autoinflammatory rheumatic diseases. <i>Journal of Autoimmunity</i> , 2022, 131, 102846.	6.5	6
10	Targeted therapies in interstitial lung disease secondary to systemic autoimmune rheumatic disease. Current status and future development. <i>Autoimmunity Reviews</i> , 2021, 20, 102742.	5.8	8
11	DNA Methylation Studies in Saliva of Patients with Sjögren's Syndrome. <i>Mediterranean Journal of Rheumatology</i> , 2021, 32, 176.	0.8	1
12	A computational workflow for the detection of candidate diagnostic biomarkers of Kawasaki disease using time-series gene expression data. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 3058-3068.	4.1	8
13	Leukocyte Immunoglobulin-Like Receptor A3 (LILRA3): A Novel Marker for Lymphoma Development among Patients with Young Onset Sjögren's Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 644.	2.4	7
14	Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's Syndrome. <i>Drugs and Aging</i> , 2021, 38, 265-284.	2.7	4
15	New frontiers in precision medicine for Sjögren's syndrome. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 127-141.	3.0	10
16	A clinical audit of pneumococcal vaccination among patients with autoimmune rheumatic diseases living in Greece: The power of awareness. <i>Vaccine</i> , 2021, 39, 1593-1597.	3.8	5
17	Exploiting the Role of Hypoxia-Inducible Factor 1 and Pseudohypoxia in the Myelodysplastic Syndrome Pathophysiology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4099.	4.1	3
18	SARS-CoV-2 Antigenemia as a Confounding Factor in Immunodiagnostic Assays: A Case Study. <i>Viruses</i> , 2021, 13, 1143.	3.3	13

#	ARTICLE	IF	CITATIONS
19	Lipoprotein-Associated Phospholipase A2: A Novel Contributor in Sjögren's Syndrome-Related Lymphoma?. <i>Frontiers in Immunology</i> , 2021, 12, 683623.	4.8	6
20	Deregulation of the Kallikrein Protease Family in the Salivary Glands of the Sjögren's Syndrome ERdj5 Knockout Mouse Model. <i>Frontiers in Immunology</i> , 2021, 12, 693911.	4.8	5
21	A computational pipeline for data augmentation towards the improvement of disease classification and risk stratification models: A case study in two clinical domains. <i>Computers in Biology and Medicine</i> , 2021, 134, 104520.	7.0	10
22	A biomarker for lymphoma development in Sjogren's syndrome: Salivary gland focus score. <i>Journal of Autoimmunity</i> , 2021, 121, 102648.	6.5	24
23	Occurrence and Antigenic Specificity of Perinuclear Anti-Neutrophil Cytoplasmic Antibodies (P-ANCA) in Systemic Autoimmune Diseases. <i>Cells</i> , 2021, 10, 2128.	4.1	3
24	Serum, but Not Saliva, CXCL13 Levels Associate With Infiltrating CXCL13+ Cells in the Minor Salivary Gland Lesions and Other Histologic Parameters in Patients With Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 705079.	4.8	8
25	COVID-19 Immunobiology: Lessons Learned, New Questions Arise. <i>Frontiers in Immunology</i> , 2021, 12, 719023.	4.8	28
26	Hypocomplementemia at Diagnosis of Pauci-immune Glomerulonephritis Is Associated With Advanced Histopathological Activity Index and High Probability of Treatment Resistance. <i>Kidney International Reports</i> , 2021, 6, 2425-2435.	0.8	13
27	COVID-19 infection among autoimmune rheumatic disease patients: Data from an observational study and literature review. <i>Journal of Autoimmunity</i> , 2021, 123, 102687.	6.5	19
28	Machine Learning Approaches on High Throughput NGS Data to Unveil Mechanisms of Function in Biology and Disease. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 605-626.	2.0	11
29	A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases. <i>Journal of Autoimmunity</i> , 2021, 125, 102743.	6.5	45
30	Sjogren's Syndrome (Ss) in Progressive Systemic Sclerosis (SSc). In <i>Clinical Practice</i> , 2021, , 281-297.	0.0	0
31	Combined seronegativity in Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
32	Searching for the "X factor" in Sjögren's syndrome female predilection. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
33	Idiopathic retroperitoneal fibrosis: clinical features, treatment modalities, relapse rate in Greek patients and a review of the literature. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	1
34	Patient-reported experience and health-related quality of life in patients with primary Sjögren's syndrome in Europe. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
35	Multiple additive regression trees with hybrid loss for classification tasks across heterogeneous clinical data in distributed environments: a case study. , 2021, 2021, 1670-1673.		4
36	A federated AI strategy for the classification of patients with Mucosa Associated Lymphoma Tissue (MALT) lymphoma across multiple harmonized cohorts. , 2021, 2021, 1666-1669.		0

#	ARTICLE	IF	CITATIONS
37	Combined seronegativity in Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 80-84.	0.8	8
38	Akt Signaling Pathway Is Activated in the Minor Salivary Glands of Patients with Primary Sjögren's Syndrome. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13441.	4.1	1
39	Searching for the "X factor" in Sjögren's syndrome female predilection. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 206-214.	0.8	7
40	Patient-reported experience and health-related quality of life in patients with primary Sjögren's syndrome in Europe. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 123-130.	0.8	1
41	EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 3-18.	0.9	307
42	Molecular and clinical spectrum of four pedigrees of TRAPS in Greece: results from a national referral center. <i>Rheumatology</i> , 2020, 59, 1241-1246.	1.9	6
43	Common and rare forms of vasculitis associated with Sjögren's syndrome. <i>Current Opinion in Rheumatology</i> , 2020, 32, 21-28.	4.3	10
44	2020 international consensus on ANCA testing beyond systemic vasculitis. <i>Autoimmunity Reviews</i> , 2020, 19, 102618.	5.8	79
45	Bioenergetic Profiling of the Differentiating Human MDS Myeloid Lineage with Low and High Bone Marrow Blast Counts. <i>Cancers</i> , 2020, 12, 3520.	3.7	9
46	Extraordinary extrahaematological manifestations of chronic myelomonocytic leukaemia. <i>Lancet</i> , The, 2020, 396, 853.	13.7	2
47	Sjögren's Syndrome: The Clinical Spectrum of Male Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 2620.	2.4	26
48	Salivary Gland Ultrasonography in Sjögren's Syndrome: A European Multicenter Reliability Exercise for the HarmonicSS Project. <i>Frontiers in Medicine</i> , 2020, 7, 581248.	2.6	26
49	Primary Sjögren's Syndrome of Early and Late Onset: Distinct Clinical Phenotypes and Lymphoma Development. <i>Frontiers in Immunology</i> , 2020, 11, 594096.	4.8	45
50	Cardio-Rheumatology: Cardiovascular Complications in Systemic Autoimmune Rheumatic Diseases / Is Inflammation the Common Link and Target?. <i>Current Vascular Pharmacology</i> , 2020, 18, 425-430.	1.7	3
51	Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1661-1663.	0.9	146
52	International Consensus on Antineutrophil Cytoplasm Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1360-1372.	5.6	36
53	Overcoming the Barriers That Obscure the Interlinking and Analysis of Clinical Data Through Harmonization and Incremental Learning. <i>IEEE Open Journal of Engineering in Medicine and Biology</i> , 2020, 1, 83-90.	2.3	9
54	Predicting Lymphoma Development by Exploiting Genetic Variants and Clinical Findings in a Machine Learning-Based Methodology With Ensemble Classifiers in a Cohort of Sjögren's Syndrome Patients. <i>IEEE Open Journal of Engineering in Medicine and Biology</i> , 2020, 1, 49-56.	2.3	4

#	ARTICLE	IF	CITATIONS
55	Interaction of Human Salivary Gland Epithelial Cells with B Lymphocytes: Implications in the Pathogenesis of Sjögren's Syndrome. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 424.	0.8	4
56	Diagnosis and Management of a Young Girl With Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) Linked to a Novel Mutation. <i>Cureus</i> , 2020, 12, e10766.	0.5	0
57	Cardio-Rheumatology: Two Collaborating Disciplines to Deal with the Enhanced Cardiovascular Risk in Autoimmune Rheumatic Diseases. <i>Current Vascular Pharmacology</i> , 2020, 18, 533-537.	1.7	3
58	Differential performance of nailfold video capillaroscopic parameters in the diagnosis and prognosis of systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 125, 29-39.	0.8	0
59	Type-III interferons in Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 245-252.	0.8	2
60	EULAR Sjögren's syndrome study group: an eSSential way to address the unmet needs of the disease. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 23-24.	0.8	2
61	One year in review 2020: pathogenesis of primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 3-9.	0.8	8
62	A Training Tool to support the management and diagnosis of Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 174-179.	0.8	0
63	Validation of thymic stromal lymphopoietin as a biomarker of primary Sjögren's syndrome and related lymphoproliferation: results in independent cohorts. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 189-194.	0.8	0
64	Response to: "miR200b-5p a new predictor of lymphoma or associated with lymphocytes infiltrate within salivary glands" by Nocturne et al. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e96-e96.	0.9	0
65	Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies. <i>Clinical Rheumatology</i> , 2019, 38, 125-132.	2.2	35
66	Trial of canakinumab, an IL-1 $\beta$ receptor antagonist, in patients with inclusion body myositis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2019, 6, e581.	6.0	17
67	Predictive markers of lymphomagenesis in Sjögren's syndrome: From clinical data to molecular stratification. <i>Journal of Autoimmunity</i> , 2019, 104, 102316.	6.5	36
68	Predicting lymphoma outcomes and risk factors in patients with primary Sjögren's Syndrome using gradient boosting tree ensembles. , 2019, 2019, 2165-2168.		8
69	Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome. <i>RMD Open</i> , 2019, 5, e001064.	3.8	53
70	Epigenetic perspectives on systemic autoimmune disease. <i>Journal of Autoimmunity</i> , 2019, 104, 102315.	6.5	50
71	Single-Cell Analysis of Human Mononuclear Phagocytes Reveals Subset-Defining Markers and Identifies Circulating Inflammatory Dendritic Cells. <i>Immunity</i> , 2019, 51, 573-589.e8.	14.3	336
72	Ablation of the Chaperone Protein ERdj5 Results in a Sjögren's Syndrome-Like Phenotype in Mice, Consistent With an Upregulated Unfolded Protein Response in Human Patients. <i>Frontiers in Immunology</i> , 2019, 10, 506.	4.8	13

#	ARTICLE	IF	CITATIONS
73	Medical data quality assessment: On the development of an automated framework for medical data curation. <i>Computers in Biology and Medicine</i> , 2019, 107, 270-283.	7.0	67
74	SP0190â€¦2019 EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SJÄ¶GRENâ€™S SYNDROME WITH TOPICAL AND SYSTEMIC THERAPIES. , 2019, , .		3
75	Lymphomagenesis in SjÄ¶gren's syndrome: Predictive biomarkers towards precision medicine. <i>Autoimmunity Reviews</i> , 2019, 18, 137-143.	5.8	54
76	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. <i>Autoimmunity Reviews</i> , 2019, 18, 93-106.	5.8	101
77	Enhancing medical data quality through data curation: a case study in primary SjÄ¶gren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 90-96.	0.8	2
78	SjÄ¶gren's syndrome towards precision medicine: the challenge of harmonisation and integration of cohorts. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 175-184.	0.8	4
79	Autoimmune epithelitis beyond the exocrine glands: an unusual case of anti-Ro/La and Scl-70 lymphocytic interstitial pneumonia. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 249-251.	0.8	1
80	The necessity of novel biomarkers in primary SjÄ¶gren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 16-18.	0.8	1
81	Variation in primary SjÄ¶gren's syndrome care among European countries. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 27-28.	0.8	1
82	Central nervous system involvement in patients with granulomatosis with polyangiitis: a single-center retrospective study. <i>Clinical Rheumatology</i> , 2018, 37, 737-747.	2.2	29
83	TNFAIP3 F127C Coding Variation in Greek Primary Sjogrenâ€™s Syndrome Patients. <i>Journal of Immunology Research</i> , 2018, 2018, 1-8.	2.2	24
84	Towards the Establishment of a Biomedical Ontology for the Primary SjÄ¶grenâ€™s Syndrome. , 2018, 2018, 4089-4092.		4
85	How can autoantibodies predict the long-term outcome of patients with interstitial lung disease? Results from a retrospective cohort study. <i>Autoimmunity Reviews</i> , 2018, 17, 1124-1133.	5.8	5
86	Low miR200b-5p levels in minor salivary glands: a novel molecular marker predicting lymphoma development in patients with SjÄ¶grenâ€™s syndrome. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrhumdis-2017-212639.	0.9	32
87	Cryoglobulinaemia. <i>Nature Reviews Disease Primers</i> , 2018, 4, 11.	30.5	143
88	Patient with ankylosing spondylitis and scleroderma renal crisis. <i>Mediterranean Journal of Rheumatology</i> , 2018, 29, 86-88.	0.8	3
89	Update on SjÄ¶grenâ€™s Syndrome 2018. <i>Mediterranean Journal of Rheumatology</i> , 2018, 29, 193-198.	0.8	5
90	Role of miR200b-5p miRNA in lymphomagenesis associated with SjÄ¶grenâ€™s syndrome (SS). <i>Mediterranean Journal of Rheumatology</i> , 2018, 29, 56-58.	0.8	2

#	ARTICLE	IF	CITATIONS
91	Autoimmune or infectious disease? That is the question. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 517-518.	0.8	1
92	Limited efficacy of targeted treatments in Sjögren's syndrome: why?. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 112, 27-28.	0.8	2
93	Severe cutaneous hand infection: <i>Mycobacterium marinum</i> in an immunosuppressed patient. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 1117.	0.8	2
94	Decrease in the ratio of polyreactive IgG titers with IgG concentration is associated with long-term complications of primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 112, 239-240.	0.8	1
95	Analysis of NLRP3, MVK and TNFRSF1A variants in adult Greek patients with autoinflammatory symptoms. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 86-89.	0.8	9
96	Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1161-1168.	0.9	200
97	Cell-specific epigenome-wide DNA methylation profile in long-term cultured minor salivary gland epithelial cells from patients with Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 625-628.	0.9	45
98	Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2017, 66, 1282-1299.	3.7	73
99	International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2017, 16, 523-541.	5.8	87
100	Insight into pathogenesis of Sjögren's syndrome: Dissection on autoimmune infiltrates and epithelial cells. <i>Clinical Immunology</i> , 2017, 182, 30-40.	3.2	67
101	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, ) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 11</i>	3.8	107
102	MTHFR gene variants and non-MALT lymphoma development in primary Sjögren's syndrome. <i>Scientific Reports</i> , 2017, 7, 7354.	3.3	28
103	Primary Sjögren's syndrome: clinical phenotypes, outcome and the development of biomarkers. <i>Immunologic Research</i> , 2017, 65, 331-344.	2.9	37
104	07.08...Contribution of mthfr gene polymorphisms in primary sjögren's syndrome related lymphomagenesis. , 2017, , .		0
105	08.37...Thrombospondin-1 is highly expressed by salivary gland epithelial cells of sjögren's syndrome patients, both constitutively and upon exposure to necrotic cells debris. , 2017, , .		0
106	Genetic Variability as a Regulator of TLR4 and NOD Signaling in Response to Bacterial Driven DNA Damage Response (DDR) and Inflammation: Focus on the Gastrointestinal (GI) Tract. <i>Frontiers in Genetics</i> , 2017, 8, 65.	2.3	11
107	Treat-to-target biologic therapy in patients with rheumatoid arthritis is more efficacious and safe compared to delayed initiation of biologics: a real-world study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 192-200.	0.8	4
108	Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 155-164.	0.8	1

#	ARTICLE	IF	CITATIONS
109	Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 719-720.	0.8	3
110	Predictors of renal histopathology in antineutrophil cytoplasmic antibody associated glomerulonephritis. <i>Journal of Autoimmunity</i> , 2016, 72, 57-64.	6.5	6
111	International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2016, 15, 1145-1160.	5.8	87
112	Increased frequency of the PTPN22W* variant in primary Sjogren's Syndrome: Association with low type I IFN scores. <i>Clinical Immunology</i> , 2016, 173, 157-160.	3.2	24
113	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 3-15.	0.9	1,114
114	Is salivary gland ultrasonography a useful tool in Sjögren's syndrome? A systematic review. <i>Rheumatology</i> , 2016, 55, 789-800.	1.9	120
115	Primary Sjögren's syndrome: Clinical phenotypes, outcome and the development of biomarkers. <i>Autoimmunity Reviews</i> , 2016, 15, 695-703.	5.8	52
116	Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity. <i>Neurotherapeutics</i> , 2016, 13, 163-178.	4.4	17
117	Autoantibodies in Sjögren's Syndrome and Laboratory Markers. <i>Rare Diseases of the Immune System</i> , 2016, , 293-308.	0.1	1
118	Panniculitis: an unusual presenting manifestation of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 126-8.	0.8	2
119	Autoantibodies in Autoimmune Diseases: Clinical and Critical Evaluation. <i>Israel Medical Association Journal</i> , 2016, 18, 519-524.	0.1	9
120	A BAFF Receptor His159Tyr Mutation in Sjögren's Syndrome-Related Lymphoproliferation. <i>Arthritis and Rheumatology</i> , 2015, 67, 2732-2741.	5.6	60
121	Sjögren's Syndrome. , 2015, , 883-889.		0
122	Saliva proteomics is a promising tool to study Sjögren syndrome. <i>Nature Reviews Rheumatology</i> , 2015, 11, 202-203.	8.0	23
123	Predicting the Outcome of Sjogren's Syndrome-Associated Non-Hodgkin's Lymphoma Patients. <i>PLoS ONE</i> , 2015, 10, e0116189.	2.5	77
124	Clinical picture, outcome and predictive factors of lymphoma in Sjögren syndrome. <i>Autoimmunity Reviews</i> , 2015, 14, 641-649.	5.8	68
125	Treatment of rheumatoid arthritis: Unraveling the conundrum. <i>Journal of Autoimmunity</i> , 2015, 65, 1-18.	6.5	99
126	Elevated expression of platelet-derived chemokines in patients with antiphospholipid syndrome. <i>Journal of Autoimmunity</i> , 2015, 65, 30-37.	6.5	39



#	ARTICLE	IF	CITATIONS
127	Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease. <i>Journal of Neuroimmunology</i> , 2015, 289, 8-11.	2.3	30
128	Immunization of mice with a peptide derived from the HTLV-1 TAX1BP1 protein induces cross-reactive antibodies against aquaporin 4. <i>Autoimmunity</i> , 2015, 48, 453-9.	2.6	6
129	Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 216-24.	0.8	32
130	The contribution of epigenetics in Sjögren's Syndrome. <i>Frontiers in Genetics</i> , 2014, 5, 71.	2.3	60
131	Diagnostic value of ultrasonography in Sjögren's syndrome. <i>Nature Reviews Rheumatology</i> , 2014, 10, 450-452.	8.0	9
132	Reduction of Intraepidermal Nerve Fiber Density (IENFD) in the skin biopsies of patients with fibromyalgia: A controlled study. <i>Journal of the Neurological Sciences</i> , 2014, 347, 143-147.	0.6	76
133	SS-B (La) Autoantibodies. , 2014, , 247-253.		0
134	B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. <i>Journal of Autoimmunity</i> , 2014, 51, 89-98.	6.5	99
135	A comprehensive review of autoantibodies in primary Sjögren's syndrome: Clinical phenotypes and regulatory mechanisms. <i>Journal of Autoimmunity</i> , 2014, 51, 67-74.	6.5	114
136	Classification criteria of Sjögren's syndrome. <i>Journal of Autoimmunity</i> , 2014, 48-49, 42-45.	6.5	58
137	Sjögren's Syndrome. , 2014, , 1069-1075.		0
138	Minor Salivary Gland Inflammatory Lesions in Sjögren Syndrome: Do They Evolve?. <i>Journal of Rheumatology</i> , 2013, 40, 1566-1571.	2.0	62
139	The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): A small pilot study. <i>Journal of the Neurological Sciences</i> , 2013, 334, 123-125.	0.6	51
140	Sjögren's syndrome. <i>International Journal of Clinical Rheumatology</i> , 2013, 8, 517-520.	0.3	1
141	Clinically Significant Renal Involvement in Primary Sjögren's Syndrome: Clinical Presentation and Outcome. <i>Arthritis and Rheumatism</i> , 2013, 65, 2945-2953.	6.7	129
142	Incidence and Prevalence of Major Central Nervous System Involvement in Systemic Lupus Erythematosus: A 3-Year Prospective Study of 370 Patients. <i>PLoS ONE</i> , 2013, 8, e55843.	2.5	83
143	Prognosis and Outcome of Non-Hodgkin Lymphoma in Primary Sjögren Syndrome. <i>Medicine (United Tj ETQq1 1 0.784314 rrgBT /Over</i>	1.0	174
144	Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 17609-17614.	7.1	140

#	ARTICLE	IF	CITATIONS
145	Punctal occlusion in Sjögren's syndrome needs clarification. <i>Nature Reviews Rheumatology</i> , 2012, 8, 752-752.	8.0	0
146	Low levels of vitamin-D are associated with neuropathy and lymphoma among patients with Sjögren's syndrome. <i>Journal of Autoimmunity</i> , 2012, 39, 234-239.	6.5	74
147	Topical and systemic medications for the treatment of primary Sjögren's syndrome. <i>Nature Reviews Rheumatology</i> , 2012, 8, 399-411.	8.0	152
148	Classification criteria for Sjögren's syndrome: A critical review. <i>Journal of Autoimmunity</i> , 2012, 39, 9-14.	6.5	122
149	Pathogenesis of Sjögren's syndrome: What we know and what we should learn. <i>Journal of Autoimmunity</i> , 2012, 39, 4-8.	6.5	191
150	Autoantibodies in Sjögren's syndrome: Clinical presentation and regulatory mechanisms. <i>Presse Medicale</i> , 2012, 41, e451-e460.	1.9	48
151	Peripheral neuropathies in Sjogren syndrome: a new reappraisal. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 798-802.	1.9	73
152	Cellular microRNAs (miRNAs) and Sjögren's syndrome: Candidate regulators of autoimmune response and autoantigen expression. <i>Journal of Autoimmunity</i> , 2011, 37, 129-135.	6.5	86
153	Association of the idiotype:antiidiotype antibody ratio with the efficacy of intravenous immunoglobulin treatment for the prevention of recurrent autoimmune-associated congenital heart block. <i>Arthritis and Rheumatism</i> , 2011, 63, 2783-2789.	6.7	30
154	Fine Epitope Specificity of Anti-erythropoietin Antibodies Reveals Molecular Mimicry With HIV-1 p17 Protein: A Pathogenetic Mechanism for HIV-1-Related Anemia. <i>Journal of Infectious Diseases</i> , 2011, 204, 902-911.	4.0	36
155	Longterm Followup After Tapering Mycophenolate Mofetil During Maintenance Treatment for Proliferative Lupus Nephritis. <i>Journal of Rheumatology</i> , 2011, 38, 1304-1308.	2.0	20
156	Pathogenetic Aspects of Primary Sjögren's Syndrome. , 2011, , 33-53.		1
157	B-cell Epitopes of Sjögren's Syndrome-Related Autoantigens Ro/SSA and La/SSB. , 2011, , 133-149.		1
158	Gynecological and Reproductive Complications in Primary Sjögren's Syndrome. , 2011, , 333-346.		0
159	Current Treatment of Extraglandular Manifestations with Disease-Modifying and Immunosuppressive Agents. , 2011, , 337-344.		0
160	Sjögren syndrome. , 2011, , 1339-1350.e1.		1
161	Idiotype, anti-idiotype network of autoantibodies. <i>Autoimmunity Reviews</i> , 2010, 9, 631-633.	5.8	44
162	Autoimmune response and target autoantigens in Sjogren's syndrome. <i>European Journal of Clinical Investigation</i> , 2010, 40, 1026-1036.	3.4	63

#	ARTICLE	IF	CITATIONS
163	RNA Recognition Motif (RRM) of La/SSB: The Bridge for Interparticle Spreading of Autoimmune Response to U1-RNP. <i>Molecular Medicine</i> , 2010, 16, 19-26.	4.4	19
164	Current aspects of pathogenesis in Sjögren's syndrome. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2010, 2, 325-334.	2.7	31
165	Treatment of Primary Sjögren Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 452.	7.4	309
166	Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome. <i>Nature Reviews Rheumatology</i> , 2010, 6, 529-537.	8.0	206
167	B-cell epitopes of the intracellular autoantigens Ro/SSA and La/SSB: Tools to study the regulation of the autoimmune response. <i>Journal of Autoimmunity</i> , 2010, 35, 256-264.	6.5	59
168	Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study. <i>Arthritis Research and Therapy</i> , 2010, 12, R208.	3.5	21
169	Salivary gland imaging techniques for the diagnosis of Sjögren's syndrome. <i>International Journal of Clinical Rheumatology</i> , 2009, 4, 321-327.	0.3	6
170	Prevalence of hepatitis C serum antibody in autoimmune diseases. <i>Journal of Autoimmunity</i> , 2009, 32, 261-266.	6.5	65
171	Functional expression of the alpha 2-macroglobulin receptor CD91 in salivary gland epithelial cells. <i>Journal of Autoimmunity</i> , 2009, 33, 141-146.	6.5	15
172	Ultrasonography of salivary glands: an evolving approach for the diagnosis of Sjögren's syndrome. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 454-455.	3.2	30
173	Neuroendocrine Dysfunction in Sjögren's Syndrome. <i>NeuroImmunoModulation</i> , 2008, 15, 37-45.	1.8	61
174	Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 732-739.	0.9	175
175	SS-B (La) AUTOANTIBODIES. , 2007, , 239-246.		0
176	Properties and function of polyreactive antibodies and polyreactive antigen-binding B cells. <i>Journal of Autoimmunity</i> , 2007, 29, 219-228.	6.5	177
177	Update on Sjögren's syndrome autoimmune epithelitis: from classification to increased neoplasias. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007, 21, 989-1010.	3.3	101
178	Sjögren's Syndrome—Study of Autoantigens and Autoantibodies. <i>Clinical Reviews in Allergy and Immunology</i> , 2007, 32, 238-251.	6.5	102
179	Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. <i>Journal of Autoimmunity</i> , 2006, 26, 165-171.	6.5	122
180	Risk factors for lymphoproliferation and mortality in Sjögren's syndrome. <i>Future Rheumatology</i> , 2006, 1, 607-616.	0.2	0

#	ARTICLE	IF	CITATIONS
181	The Role of Chaperone Proteins in Autoimmunity. <i>Annals of the New York Academy of Sciences</i> , 2006, 1088, 52-64.	3.8	32
182	Anti-La/SSB antiidiotypic antibodies in maternal serum: A marker of low risk for neonatal lupus in an offspring. <i>Arthritis and Rheumatism</i> , 2006, 54, 2228-2234.	6.7	40
183	Autoantibodies to intracellular autoantigens and their B-cell epitopes: Molecular Probes to Study the Autoimmune Response. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2006, 43, 203-248.	6.1	40
184	Hepatitis C virus, Sjögren's syndrome and B-cell lymphoma: linking infection, autoimmunity and cancer. <i>Autoimmunity Reviews</i> , 2005, 4, 8-15.	5.8	85
185	Zinc Ion Dependent B-Cell Epitope, Associated with Primary Sjogren's Syndrome, Resides within the Putative Zinc Finger Domain of Ro60kD Autoantigen: A Physical and Immunologic Properties. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 4327-4334.	6.4	13
186	The clinical value of intracellular autoantigens B-cell epitopes in systemic rheumatic diseases. <i>Clinica Chimica Acta</i> , 2004, 340, 1-25.	1.1	61
187	Idiotypic anti-idiotypic circuit in non-autoimmune mice after immunization with the epitope and complementary epitope 289-308aa of La/SSB: implications for the maintenance and perpetuation of the anti-La/SSB response. <i>Journal of Autoimmunity</i> , 2003, 21, 17-26.	6.5	35
188	Linear epitopes of two different autoantigens-La/SSB and myelin basic protein with a high degree of molecular similarity, cause different humoral immune responses. <i>Journal of Autoimmunity</i> , 2003, 21, 47-57.	6.5	8
189	Unmasking the Anti-La/SSB Response in Sera From Patients With Sjogren's Syndrome by Specific Blocking of Anti-idiotypic Antibodies to La/SSB Antigenic Determinants. <i>Molecular Medicine</i> , 2002, 8, 293-305.	4.4	48
190	Unmasking the anti-La/SSB response in sera from patients with Sjogren's syndrome by specific blocking of anti-idiotypic antibodies to La/SSB antigenic determinants. <i>Molecular Medicine</i> , 2002, 8, 293-305.	4.4	16
191	Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2002, 29, 2129-35.	2.0	80
192	Lymphoid chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sjögren's syndrome patients: Possible participation in lymphoid structure formation. <i>Arthritis and Rheumatism</i> , 2001, 44, 408-418.	6.7	165
193	Clinically Significant and Biopsy-Documented Renal Involvement in Primary Sjogren Syndrome. <i>Medicine (United States)</i> , 2000, 79, 241-249.	1.0	170
194	Sjögren's Syndrome: Autoantibodies to Cellular Antigens. <i>International Archives of Allergy and Immunology</i> , 2000, 123, 46-57.	2.1	63
195	Autoimmune hemolytic anemia in patients with systemic lupus erythematosus. <i>American Journal of Medicine</i> , 2000, 108, 198-204.	1.5	133
196	Autoantibodies to La/SSB in Patients with Primary Sjögren's Syndrome (pSS) are Associated with Upregulation of La/SSB mRNA in Minor Salivary Gland Biopsies (MSGs). <i>Journal of Autoimmunity</i> , 1999, 13, 429-434.	6.5	29
197	Sjögren's Syndrome. <i>Advances in Experimental Medicine and Biology</i> , 1999, , 127-134.	1.6	50
198	A major Sm epitope anchored to sequential oligopeptide carriers is a suitable antigenic substrate to detect anti-Sm antibodies. <i>Journal of Immunological Methods</i> , 1998, 220, 59-68.	1.4	28

#	ARTICLE	IF	CITATIONS
199	Autoantibodies to human recombinant erythropoietin in patients with systemic lupus erythematosus. Correlation with anemia. <i>Arthritis and Rheumatism</i> , 1997, 40, 2212-2216.	6.7	74
200	Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 1996, 39, 767-772.	6.7	230
201	Autoantibodies to hmg-17 nucleosomal protein in autoimmune rheumatic diseases. <i>Arthritis and Rheumatism</i> , 1993, 36, 955-961.	6.7	28
202	Idiopathic retroperitoneal fibrosis: clinical features, treatment modalities, relapse rate in Greek patients and a review of the literature. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	1